OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kuykendall on Treatment Considerations with Ruxolitinib in Myelofibrosis

October 24th 2022

Andrew Kuykendall, MD, discusses treatment considerations with ruxolitinib in myelofibrosis.

Dr. Aragon-Ching on the Future Implications of the JAVELIN Bladder 100 Trial in Urothelial Cancer

October 24th 2022

Jeanny B. Aragon-Ching, MD, FACP, discusses the future implications of the phase 3 JAVELIN Bladder 100 trial in urothelial cancer.

Dr. Stone on the Use of E-selectin as a Target to Overcome Treatment Resistance in AML

October 24th 2022

Richard M. Stone, MD, discusses potential ways to address drug resistance in acute myeloid leukemia by targeting E-selectin.

Dr. Varga on Current Clinical Trials for Patients with Relapsed/Refractory Multiple Myeloma

October 24th 2022

Cindy Varga, MD, discusses several exciting clinical trials at the Levine Cancer Institute for patients with relapsed/refractory multiple myeloma with acquired resistance to BCMA-directed therapy.

Dr. McKenzie on Navigating the Landscape of Biomarker Testing in NSCLC

October 24th 2022

Andrew McKenzie, PhD, discusses the variety of molecular testing modalities in patients with metastatic non–small cell lung cancer.

Dr. Stollenwerk on the Effect of Robotic Bronchoscopy on Lung Cancer Diagnosis

October 24th 2022

Nicholas Stollenwerk, MD, discusses the real-world effects of robotic-assisted bronchoscopy on diagnosis and treatment for patients with lung cancer.

Dr. Schenk on the Effect of Nivolumab Plus Relatlimab in Basal Cell Carcinoma

October 21st 2022

Kara M. Schenk, MD, discusses the effect of nivolumab plus relatlimab in advanced basal cell carcinoma.

Dr. Lipson on the Impact of Preoperative Nivolumab Plus Relatlimab in NSCLC

October 21st 2022

Evan J. Lipson, MD, discusses the effect of preoperative nivolumab plus relatlimab in resectable non-small cell lung cancer (NSCLC).

Dr. Garassino on Updates From the KEYNOTE-189 Trial in NSCLC

October 21st 2022

Marina Chiara Garassino, MD, discusses updates from the phase 3 KEYNOTE-189 trial in non–small cell lung cancer.

Dr. Chen on FLASH Trial Results in CTCL

October 21st 2022

Pei-Ling Chen, MD, PhD, gives her perspective on results from the phase 3 FLASH trial investigating synthetic hypericin in CTCL.

Dr. Chen Explores Possible Genomic Basis for Racial Disparities in CTCL Outcomes

October 21st 2022

Pei-Ling Chen, MD, PhD, discusses genomic findings that may explain poorer outcomes for Black patients with CTCL.

Dr. Chen on Identifying Malignant T-Cell Signatures in CTCL

October 21st 2022

Pei-Ling Chen, MD, PhD, discusses findings from a study the multiomics of patients with transformed CTCL that she led at Moffitt Cancer Center.

Dr. Chen Discusses Management of Early Stage, Advanced CTCL

October 21st 2022

Pei-Ling Chen, MD, PhD, says management of cutaneous T-cell lymphoma requires a multidisciplinary team of specialists including dermatologists and radiation oncologists.

Dr. Chen Discusses Racial Disparities in CTCL

October 21st 2022

Pei-Ling Chen, MD, PhD, discusses epidemiology and racial disparities in CTCL.

Dr. Chen Highlights Incidence of CTCL

October 21st 2022

Pei-Ling Chen, MD, PhD, discusses the incidence of CTCL.

Dr. Giaconne on the Lack of Funding for Rare Cancers Research

October 21st 2022

Giuseppe Giaccone, MD, PhD, highlights the difficulties with funding for research focused on rare cancers.

Dr. He Discusses Discovery of Cancer-Inducing Mutation in Thymic Epithelial Cells

October 21st 2022

Yongfeng He, PhD, discusses the identification of the GTF2I L424H mutation in mouse models of thymic cancer.

Dr. He Discusses Potential Therapeutic Uses for GTF2I L424+ Thymic Cancers

October 21st 2022

Yongfeng He, PhD, discusses how the presence of the GTF2I L424H mutation in thymic epithelial cells induced thymic tumors in mouse models.

Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIs

October 21st 2022

Amanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.

Emily Skotte, MSN on Rash Management in Patients Treated With EGFR TKIs

October 21st 2022

Emily Skotte, MSN, discusses common ways to manage the rashes that may occur as adverse effects in patients treated with EGFR TKIs.